| Followers | 129 |
| Posts | 7636 |
| Boards Moderated | 1 |
| Alias Born | 02/25/2014 |
Thursday, March 12, 2020 11:05:40 AM
Ask Jon about this: BOCA RATON, FL, March 06, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group (OTC PINK: CTYX) issued a shareholder update today regarding recent corporate developments including management and Board of Director changes.
SunMed Advisors, LLC has recently acquired majority control of CTYX through the purchase of Series A Preferred stock from the two principal holders of CTYX.
Jon Pevzner, former President and Director, has resigned and Paul M. Michaels was appointed Interim CEO and Director. Mr. Michaels has business and investment experience in Japan and the U.S. with noteworthy expertise in the Life Sciences sector. He has completed transactions involving companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead Sciences.
Dr. Barry A. Ginsberg and Brandon Michaels join Mr. Michaels on the Board.
CTYX is currently in the process of updating financials to become compliant with OTCMarkets and has appointed Jonathan D. Leinwand, PA as Legal Counsel.
CTYX will continue to update shareholders on a new business plan through news releases, website updates and OTCMarkets filings as the company moves forward.
Investor Database for Future Press Releases and Industry Updates
Interested investors and shareholders are invited to be added to the corporate e-mail database for corporate press releases and periodic industry updates by sending an e-mail to: investorrelations@connectyx.com
About SunMed Advisors, LLC ( https://sunmedadvisors.com/ )
SunMed Advisors is a Life Science and Technology consulting firm that helps create maximum corporate value with strategic initiatives and a leading advisor on Pre-Commercial and Commercial-Stage licensing deals. SunMed brings value to all stages of licensing transactions, from sourcing through closing.
http://search.sunbiz.org/Inquiry/CorporationSearch/GetDocument?aggregateId=domp-p07000118707-cd4afd40-6c64-433b-9f3e-72eccc2ec9b6&transactionId=p07000118707-88db6848-a7a9-4873-9341-bb4668d4a40d&formatType=PDF
SunMed Advisors, LLC has recently acquired majority control of CTYX through the purchase of Series A Preferred stock from the two principal holders of CTYX.
Jon Pevzner, former President and Director, has resigned and Paul M. Michaels was appointed Interim CEO and Director. Mr. Michaels has business and investment experience in Japan and the U.S. with noteworthy expertise in the Life Sciences sector. He has completed transactions involving companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead Sciences.
Dr. Barry A. Ginsberg and Brandon Michaels join Mr. Michaels on the Board.
CTYX is currently in the process of updating financials to become compliant with OTCMarkets and has appointed Jonathan D. Leinwand, PA as Legal Counsel.
CTYX will continue to update shareholders on a new business plan through news releases, website updates and OTCMarkets filings as the company moves forward.
Investor Database for Future Press Releases and Industry Updates
Interested investors and shareholders are invited to be added to the corporate e-mail database for corporate press releases and periodic industry updates by sending an e-mail to: investorrelations@connectyx.com
About SunMed Advisors, LLC ( https://sunmedadvisors.com/ )
SunMed Advisors is a Life Science and Technology consulting firm that helps create maximum corporate value with strategic initiatives and a leading advisor on Pre-Commercial and Commercial-Stage licensing deals. SunMed brings value to all stages of licensing transactions, from sourcing through closing.
http://search.sunbiz.org/Inquiry/CorporationSearch/GetDocument?aggregateId=domp-p07000118707-cd4afd40-6c64-433b-9f3e-72eccc2ec9b6&transactionId=p07000118707-88db6848-a7a9-4873-9341-bb4668d4a40d&formatType=PDF
Recent CUBT News
- Curative Biotechnology Advances Translational Ophthalmology Program Through PennVet Research Agreement • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy • GlobeNewswire Inc. • 04/15/2026 12:08:00 PM
- Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting • GlobeNewswire Inc. • 03/23/2026 11:05:00 PM
- Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- Curative Biotechnology Announces Canadian Patent Allowance • GlobeNewswire Inc. • 01/23/2026 01:45:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 12/22/2025 06:40:01 PM
- Curative Biotechnology, Inc. Announces Letter to Shareholders • GlobeNewswire Inc. • 11/18/2025 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/01/2025 08:07:47 PM
